<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cambridge Cognition Holdings Plc — News on 6ix</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc</link>
<description>Latest news and press releases for Cambridge Cognition Holdings Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 14:16:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cambridge-cognition-holdings-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e12b78dffbe2df1264e1.webp</url>
<title>Cambridge Cognition Holdings Plc</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc</link>
</image>
<item>
<title>Posting of Annual Report & Notice of AGM</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/posting-of-annual-report-and-notice-of-agm-168</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/posting-of-annual-report-and-notice-of-agm-168</guid>
<pubDate>Fri, 24 Apr 2026 14:16:00 GMT</pubDate>
<description>Cambridge Cognition Holdings plc has published its Annual Report and Accounts for the year ended 31 December 2025, along with the Notice of its Annual General Meeting, which will be held on 21 May 2026. These documents are available on the company's website for shareholders.
Disclaimer*</description>
</item>
<item>
<title>Results for the year ended 31 December 2025</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/results-for-the-year-ended-31-december-2025-14</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/results-for-the-year-ended-31-december-2025-14</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>Cambridge Cognition Holdings plc reported a return to growth in new sales orders, which increased by 73% to £12.8 million in 2025, and an order book up 21% to £16.5 million, though revenue decreased by 10% to approximately £9.4 million due to a weaker opening order book. The company experienced an adjusted EBITDA loss of £0.5 million, an increase from the prior year's loss of £43,000, but successfully raised £1.1 million in gross proceeds through a placing. Borrowings were reduced to £0.9 millio</description>
</item>
<item>
<title>Notice of Results</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/notice-of-results-386</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/notice-of-results-386</guid>
<pubDate>Tue, 07 Apr 2026 06:01:00 GMT</pubDate>
<description>Cambridge Cognition Holdings plc announced that it will release its full-year results for the period ending 31 December 2025 on Monday, 13 April 2026. This upcoming announcement is the primary financial news from the company, and investors will be looking for details on its performance in driving scientific discovery, accelerating drug development, and improving patient care through its digital cognitive assessments.
Disclaimer*</description>
</item>
<item>
<title>Block Listing Return</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/block-listing-return-37</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/block-listing-return-37</guid>
<pubDate>Wed, 01 Apr 2026 06:00:00 GMT</pubDate>
<description>Cambridge Cognition Holdings plc has filed a block listing return for its share options scheme, reporting that as of March 31, 2026, there were 466,316 ordinary shares remaining unallotted under the scheme. This figure represents the balance from the previous return of 466,316 shares, with no increase to the block scheme and no securities issued or allotted during the period from October 1, 2025, to March 31, 2026.
Disclaimer*</description>
</item>
<item>
<title>Monument Therapeutics MT1988 First Patient Dosed</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/monument-therapeutics-mt1988-first-patient-dosed</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/monument-therapeutics-mt1988-first-patient-dosed</guid>
<pubDate>Wed, 11 Mar 2026 07:00:00 GMT</pubDate>
<description>Cambridge Cognition Holdings plc announced that its 20% owned associate, Monument Therapeutics, has dosed the first patient in a clinical trial for MT1988, a potential treatment for individuals at clinical high risk for psychosis. This randomized, placebo-controlled study will enroll 150 participants over an eight-week period to evaluate MT1988's efficacy in improving cognitive symptoms, utilizing both clinical and cognitive biomarkers, with Cambridge Cognition's digital assessment technologies </description>
</item>
<item>
<title>Cambridge Cognition Partners With Ivory to Scale Early Cognitive Screening With CANTAB Pathway™ in India</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/cambridge-cognition-partners-ivory-scale-171300574</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/cambridge-cognition-partners-ivory-scale-171300574</guid>
<pubDate>Tue, 17 Feb 2026 17:13:00 GMT</pubDate>
<description>BENGALURU, India & CAMBRIDGE, England, February 17, 2026--Cambridge Cognition Holdings plc ("Cambridge Cognition") (AIM: COG), the neuroscience technology company specialising in digital cognitive assessments, and Ivory, a venture-backed brain health company headquartered in India, announce an agreement for the commercialisation of CANTAB Pathway™ across the healthcare and consumer health markets in India.</description>
</item>
<item>
<title>Commercialisation Agreement</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/commercialisation-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/commercialisation-agreement</guid>
<pubDate>Mon, 16 Feb 2026 07:00:00 GMT</pubDate>
<description>Cambridge Cognition Holdings plc has partnered with Ivory to commercialize its CANTAB Pathway™ digital cognitive assessments across India's healthcare and consumer health markets, targeting a population of approximately 1.47 billion, including an estimated 34 million individuals aged over 60 who may have cognitive impairment. This strategic expansion leverages Ivory's brain health platform and distribution network to address a significant unmet need for early cognitive screening in a growing, he</description>
</item>
<item>
<title>Change of Joint Broker</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/change-of-joint-broker-8</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/change-of-joint-broker-8</guid>
<pubDate>Mon, 09 Feb 2026 07:00:00 GMT</pubDate>
<description>Cambridge Cognition Holdings plc has announced the immediate appointment of Singer Capital Markets as Joint Corporate Broker, following the transfer of Dowgate Capital's corporate broking, advisory, and research team to Singer Capital Markets. This change in brokerage is the primary focus of the announcement and may impact how the company's shares are covered and traded.
Disclaimer*</description>
</item>
<item>
<title>Trading Update</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/trading-update-754</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/trading-update-754</guid>
<pubDate>Mon, 19 Jan 2026 07:00:00 GMT</pubDate>
<description>Cambridge Cognition Holdings plc reported a strong increase in new sales orders for the year ended 31 December 2025, up 73% to £12.8m, and its order book grew 25% to £16.9m, with £8.5m to £9.0m anticipated as revenue in 2026. Despite revenues of approximately £9.4m, a 10% decrease from 2024, the company's adjusted EBITDA loss was in line with market expectations. Cambridge Cognition successfully raised £1.1m in gross proceeds through a placing in August, resulting in a cash balance of £1.1m and </description>
</item>
<item>
<title>Change of Auditor</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/change-of-auditor-170</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/change-of-auditor-170</guid>
<pubDate>Wed, 05 Nov 2025 07:01:00 GMT</pubDate>
<description>Change of Auditor.</description>
</item>
<item>
<title>Exercise of Options and Total Voting Rights</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/exercise-of-options-and-total-voting-rights-67</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/exercise-of-options-and-total-voting-rights-67</guid>
<pubDate>Mon, 29 Sep 2025 06:00:00 GMT</pubDate>
<description>Cambridge Cognition Holdings PLC announced the issuance and allotment of 589,287 new ordinary shares, each with a nominal value of 1 pence, following the exercise of share options. Application has been made for these new shares to be admitted to trading on AIM, with dealings expected to commence on September 30, 2025. Following this admission, the company's total number of ordinary shares in issue will be 46,629,700. This figure can be used by shareholders to determine if they need to notify the</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/holdings-in-company-1099</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/holdings-in-company-1099</guid>
<pubDate>Fri, 26 Sep 2025 08:59:00 GMT</pubDate>
<description>Maven Capital Partners UK LLP is issuing a correction to a previous notification regarding Cambridge Cognition Holdings PLC. The event prompting the notification is a change in the breakdown of voting rights. On September 2, 2025, Maven Capital Partners' total voting rights attached to shares reached 3.6489681%, representing 1,680,000 voting rights. This corrects the previously reported figure of 4.006000% which also represented 1,680,000 voting rights. The corrected total includes 3.6489681% of</description>
</item>
<item>
<title>Investor Presentation via Investor Meet Company</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/investor-presentation-via-investor-meet-company-113</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/investor-presentation-via-investor-meet-company-113</guid>
<pubDate>Mon, 01 Sep 2025 09:58:00 GMT</pubDate>
<description>Cambridge Cognition Holdings PLC announced that Rob Baker, Group Chief Operating Officer, and Ronald Openshaw, Chief Financial Officer, will deliver a live presentation regarding the Interim Results via Investor Meet Company on September 3, 2025, at 11:00 BST. The presentation is accessible to both current and prospective shareholders. Questions can be submitted through the Investor Meet Company dashboard before September 2, 2025, at 09:00 BST, or during the live presentation. Interested parties</description>
</item>
<item>
<title>£1.12m Placing & Subscription, TVR & PDMR Dealings</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/pound112m-placing-and-subscription-tvr-and-pdmr-dealings</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/pound112m-placing-and-subscription-tvr-and-pdmr-dealings</guid>
<pubDate>Thu, 28 Aug 2025 09:45:00 GMT</pubDate>
<description>Cambridge Cognition Holdings PLC announced a placing and subscription, raising approximately £1.12 million. The company issued 4,100,000 new ordinary shares at a price of 27.25p per share. Of the total, 1,118,226 shares were placed with existing institutional investors, raising approximately £0.31 million. A substantial shareholder, directors, and PDMRs subscribed for 2,981,774 new ordinary shares, generating approximately £0.81 million. The issue price represents a 4.81% premium over the previo</description>
</item>
<item>
<title>Monument Therapeutics Partnership with FNIH</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/monument-therapeutics-partnership-with-fnih</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/monument-therapeutics-partnership-with-fnih</guid>
<pubDate>Tue, 19 Aug 2025 09:10:00 GMT</pubDate>
<description>Cambridge Cognition Holdings plc (AIM: COG) announced that Monument Therapeutics, in which the Group holds a 20% stake valued at £1.8 million, has partnered with the Foundation for the National Institutes of Health (FNIH) for a clinical trial of MT1988, a novel schizophrenia treatment. The trial is part of the FNIH's Accelerating Medicines Partnership® Schizophrenia program, a public-private collaboration with $44 million in committed investment. Cambridge Cognition's technology played a key ro</description>
</item>
<item>
<title>Launch of Speaker Identification Solution</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/launch-of-speaker-identification-solution</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/launch-of-speaker-identification-solution</guid>
<pubDate>Tue, 12 Aug 2025 06:00:00 GMT</pubDate>
<description>Launch of Speaker Identification Solution.</description>
</item>
<item>
<title>Trading update for period ended 30 June 2025</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/trading-update-for-period-ended-30-june-2025</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/trading-update-for-period-ended-30-june-2025</guid>
<pubDate>Thu, 31 Jul 2025 06:00:00 GMT</pubDate>
<description>Trading update for period ended 30 June 2025.</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/result-of-agm-1008</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/result-of-agm-1008</guid>
<pubDate>Fri, 27 Jun 2025 11:27:00 GMT</pubDate>
<description>Result of AGM.</description>
</item>
<item>
<title>Monument Therapeutics Success in Phase I Results</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/monument-therapeutics-success-in-phase-i-results</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/monument-therapeutics-success-in-phase-i-results</guid>
<pubDate>Tue, 24 Jun 2025 06:00:00 GMT</pubDate>
<description>Monument Therapeutics Success in Phase I Results.</description>
</item>
<item>
<title>Notice of AGM</title>
<link>https://6ix.com/company/cambridge-cognition-holdings-plc/news/notice-of-agm-537</link>
<guid isPermaLink="true">https://6ix.com/company/cambridge-cognition-holdings-plc/news/notice-of-agm-537</guid>
<pubDate>Wed, 04 Jun 2025 06:00:00 GMT</pubDate>
<description>Notice of AGM.</description>
</item>
</channel>
</rss>